Discovery of salermide-related sirtuin inhibitors: Binding mode studies and antiproliferative effects in cancer cells including cancer stem cells

Journal of Medicinal Chemistry

Volumn 55, Issue 24, 2012, Pages 10937-10947

  Rotili, Dante ^a   Tarantino, Domenico ^a   Nebbioso, Angela ^b   Paolini, Chantal ^c   Huidobro, Covadonga ^d   Lara, Ester ^e   Mellini, Paolo ^a,f   Lenoci, Alessia ^a   Pezzi, Riccardo ^a   Botta, Giorgia ^a   Lahtela Kakkonen, Maija ^f   Poso, Antti ^f   Steinkühler, Christian ^c   Gallinari, Paola ^c   De Maria, Ruggero ^g   Fraga, Mario ^d,e   Esteller, Manel ^h,i,j   Altucci, Lucia ^b,k   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Exiris Srl   (Italy)

^d DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^e CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^k INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAMBINOL; HYDROLASE INHIBITOR; JGB1741; MC2141; SIRTINOL; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STEM CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG BINDING; GLIOBLASTOMA; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GRANULOCYTES; HUMANS; MOLECULAR DOCKING SIMULATION; NAPHTHOLS; NEOPLASTIC STEM CELLS; PHENYLPROPIONATES; PROTEIN BINDING; SIRTUIN 1; SIRTUIN 2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871662210     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3011614     Document Type: Article

References (58)

1. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nature Rev. Drug Discovery 2012, 11, 384-400
2. Jenuwein, T.; Allis, C. D. Translating the histone code Science 2001, 293, 1074-1080 (Pubitemid 32758077)
3. Jones, P. A.; Baylin, S. B. The epigenomics of cancer Cell 2007, 128, 683-692 (Pubitemid 46273572)
4. Yang, X. J.; Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention Oncogene 2007, 26, 5310-5318 (Pubitemid 47255917)
5. Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy Med. Res. Rev. 2005, 25, 261-309 (Pubitemid 40489663)
6. Zheng, W. Mechanism-based modulator discovery for sirtuin-catalyzed deacetylation reaction. Mini-Rev. Med. Chem. 2012, Jul 30, PMID 22876953.
7. Cen, Y.; Youn, D. Y.; Sauve, A. A. Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications Curr. Med. Chem. 2011, 18, 1919-1935
8. Carafa, V.; Nebbioso, A.; Altucci, L. Sirtuins and disease: the road ahead Front. Pharmacol. 2012, 3, 4
9. Haigis, M. C.; Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance Annu. Rev. Pathol. 2010, 5, 253-295
10. Guarente, L.; Franklin, H. Epstein Lecture: Sirtuins, aging, and medicine N. Engl. J. Med. 2011, 364, 2235-2244
11. Mostoslavsky, R.; Esteller, M.; Vaquero, A. At the crossroad of lifespan, calorie restriction, chromatin and disease: meeting on sirtuins Cell Cycle 2010, 9, 1907-1912
12. Cen, Y. Sirtuins inhibitors: the approach to affinity and selectivity Biochim. Biophys. Acta 2010, 1804, 1635-1644
13. Balcerczyk, A.; Pirola, L. Therapeutic potential of activators and inhibitors of sirtuins Biofactors 2010, 36, 383-393
14. Stunkel, W.; Campbell, R. M. Sirtuin 1 (SIRT1): the misunderstood HDAC J. Biomol. Screening 2011, 16, 1153-1169
15. Jung-Hynes, B.; Nihal, M.; Zhong, W.; Ahmad, N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J. Biol. Chem. 2009, 284, 3823-3832
16. Chen, J.; Zhang, B.; Wong, N.; Lo, A. W.; To, K. F.; Chan, A. W.; Ng, M. H.; Ho, C. Y.; Cheng, S. H.; Lai, P. B.; Yu, J.; Ng, H. K.; Ling, M. T.; Huang, A. L.; Cai, X. F.; Ko, B. C. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth Cancer Res. 2011, 71, 4138-4149
17. Jang, K. Y.; Kim, K. S.; Hwang, S. H.; Kwon, K. S.; Kim, K. R.; Park, H. S.; Park, B. H.; Chung, M. J.; Kang, M. J.; Lee, D. G.; Moon, W. S. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours Pathology 2009, 41, 366-371
18. Cha, E. J.; Noh, S. J.; Kwon, K. S.; Kim, C. Y.; Park, B. H.; Park, H. S.; Lee, H.; Chung, M. J.; Kang, M. J.; Lee, D. G.; Moon, W. S.; Jang, K. Y. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma Clin. Cancer Res. 2009, 15, 4453-4459
19. Nosho, K.; Shima, K.; Irahara, N.; Kure, S.; Firestein, R.; Baba, Y.; Toyoda, S.; Chen, L.; Hazra, A.; Giovannucci, E. L.; Fuchs, C. S.; Ogino, S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer Mod. Pathol. 2009, 22, 922-932
20. Kabra, N.; Li, Z.; Chen, L.; Li, B.; Zhang, X.; Wang, C.; Yeatman, T.; Coppola, D.; Chen, J. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer J. Biol. Chem. 2009, 284, 18210-18217
21. Powell, M. J.; Casimiro, M. C.; Cordon-Cardo, C.; He, X.; Yeow, W. S.; Wang, C.; McCue, P. A.; McBurney, M. W.; Pestell, R. G. Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation Cancer Res. 2011, 71, 964-975
22. Herranz, D.; Serrano, M. SIRT1: recent lessons from mouse models Nature Rev. Cancer 2010, 10, 819-823
23. Nemoto, S.; Fergusson, M. M.; Finkel, T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway Science 2004, 306, 2105-2108 (Pubitemid 40007664)
24. Wang, R. H.; Sengupta, K.; Li, C.; Kim, H. S.; Cao, L.; Xiao, C.; Kim, S.; Xu, X.; Zheng, Y.; Chilton, B.; Jia, R.; Zheng, Z. M.; Appella, E.; Wang, X. W.; Ried, T.; Deng, C. X. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice Cancer Cell 2008, 14, 312-323
25. Rajendran, R.; Garva, R.; Krstic-Demonacos, M.; Demonacos, C. Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription J. Biomed. Biotechnol. 2011, 2011, 368276
26. Firestein, R.; Blander, G.; Michan, S.; Oberdoerffer, P.; Ogino, S.; Campbell, J.; Bhimavarapu, A.; Luikenhuis, S.; de Cabo, R.; Fuchs, C.; Hahn, W. C.; Guarente, L. P.; Sinclair, D. A. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth PLoS One 2008, 3, e2020
27. Boily, G.; He, X. H.; Pearce, B.; Jardine, K.; McBurney, M. W. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol Oncogene 2009, 28, 2882-2893
28. Li, Y.; Matsumori, H.; Nakayama, Y.; Osaki, M.; Kojima, H.; Kurimasa, A.; Ito, H.; Mori, S.; Katoh, M.; Oshimura, M.; Inoue, T. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis Genes Cells 2011, 16, 34-45
29. He, X.; Nie, H.; Hong, Y.; Sheng, C.; Xia, W.; Ying, W. SIRT2 activity is required for the survival of C6 glioma cells Biochem. Biophys. Res. Commun. 2012, 417, 468-472
30. Zuo, Q.; Wu, W.; Li, X.; Zhao, L.; Chen, W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin Oncol. Rep. 2012, 27, 819-824
31. Peck, B.; Chen, C. Y.; Ho, K. K.; Di Fruscia, P.; Myatt, S. S.; Coombes, R. C.; Fuchter, M. J.; Hsiao, C. D.; Lam, E. W. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2 Mol. Cancer Ther. 2010, 9, 844-855
32. Bitterman, K. J.; Anderson, R. M.; Cohen, H. Y.; Latorre-Esteves, M.; Sinclair, D. A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1 J. Biol. Chem. 2002, 277, 45099-45107 (Pubitemid 36159111)
33. Grozinger, C. M.; Chao, E. D.; Blackwell, H. E.; Moazed, D.; Schreiber, S. L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening J. Biol. Chem. 2001, 276, 38837-38843
34. Heltweg, B.; Gatbonton, T.; Schuler, A. D.; Posakony, J.; Li, H.; Goehle, S.; Kollipara, R.; Depinho, R. A.; Gu, Y.; Simon, J. A.; Bedalov, A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes Cancer Res. 2006, 66, 4368-4377
35. Kalle, A. M.; Mallika, A.; Badiger, J.; Alinakhi; Talukdar, P.; Sachchidanand. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells Biochem. Biophys. Res. Commun. 2010, 401, 13-19
36. Rotili, D.; Tarantino, D.; Carafa, V.; Lara, E.; Meade, S.; Botta, G.; Nebbioso, A.; Schemies, J.; Jung, M.; Kazantsev, A. G.; Esteller, M.; Fraga, M. F.; Altucci, L.; Mai, A. Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors ChemMedChem 2010, 5, 674-677
37. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 2008, 13, 454-463 (Pubitemid 351609441)
38. Blum, C. A.; Ellis, J. L.; Loh, C.; Ng, P. Y.; Perni, R. B.; Stein, R. L. SIRT1 modulation as a novel approach to the treatment of diseases of aging J. Med. Chem. 2011, 54, 417-432
39. Schemies, J.; Uciechowska, U.; Sippl, W.; Jung, M. NAD(+)-dependent histone deacetylases (sirtuins) as novel therapeutic targets Med. Res. Rev. 2010, 30, 861-889
40. Villalba, J. M.; Alcain, F. J. Sirtuin activators and inhibitors Biofactors 2012, 38, 349-359
41. Mai, A.; Massa, S.; Lavu, S.; Pezzi, R.; Simeoni, S.; Ragno, R.; Mariotti, F. R.; Chiani, F.; Camilloni, G.; Sinclair, D. A. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors J. Med. Chem. 2005, 48, 7789-7795 (Pubitemid 41698818)
42. Mai, A.; Valente, S.; Meade, S.; Carafa, V.; Tardugno, M.; Nebbioso, A.; Galmozzi, A.; Mitro, N.; De Fabiani, E.; Altucci, L.; Kazantsev, A. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors J. Med. Chem. 2009, 52, 5496-5504
43. Pasco, M. Y.; Rotili, D.; Altucci, L.; Farina, F.; Rouleau, G. A.; Mai, A.; Neri, C. Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues J. Med. Chem. 2010, 53, 1407-1411
44. Rotili, D.; Carafa, V.; Tarantino, D.; Botta, G.; Nebbioso, A.; Altucci, L.; Mai, A. Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile Bioorg. Med. Chem. 2011, 19, 3659-3668
45. Orecchia, A.; Scarponi, C.; Di Felice, F.; Cesarini, E.; Avitabile, S.; Mai, A.; Mauro, M. L.; Sirri, V.; Zambruno, G.; Albanesi, C.; Camilloni, G.; Failla, C. M. Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells PLoS One 2011, 6, e24307
46. Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M. L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Imhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect Oncogene 2009, 28, 781-791
47. Nguyen, L. V.; Vanner, R.; Dirks, P.; Eaves, C. J. Cancer stem cells: an evolving concept Nature Rev. Cancer 2012, 12, 133-143
48. Prud'homme, G. J. Cancer stem cells and novel targets for antitumor strategies Curr. Pharm. Des. 2012, 18, 2838-2849
49. Kubota, T.; Sawada, N.; Zhou, L.; Welch, C. J. Enantioseparation of benzazoles and benzanilides on polysaccharide-based chiral columns Chirality 2010, 22, 382-388
50. Charton, J.; Girault-Mizzi, S.; Debreu-Fontaine, M. A.; Foufelle, F.; Hainault, I.; Bizot-Espiard, J. G.; Caignard, D. H.; Sergheraert, C. Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators Bioorg. Med. Chem. 2006, 14, 4490-4518 (Pubitemid 43728675)
51. Yang, Q.; Olmsted, C.; Borhan, B. Absolute stereochemical determination of chiral carboxylic acids Org. Lett. 2002, 4, 3423-3426
52. Bissinger, E. M.; Heinke, R.; Spannhoff, A.; Eberlin, A.; Metzger, E.; Cura, V.; Hassenboehler, P.; Cavarelli, J.; Schule, R.; Bedford, M. T.; Sippl, W.; Jung, M. Acyl derivatives of p -aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1 Bioorg. Med. Chem. 2011, 19, 3717-3731
53. Napper, A. D.; Hixon, J.; McDonagh, T.; Keavey, K.; Pons, J. F.; Barker, J.; Yau, W. T.; Amouzegh, P.; Flegg, A.; Hamelin, E.; Thomas, R. J.; Kates, M.; Jones, S.; Navia, M. A.; Saunders, J. O.; DiStefano, P. S.; Curtis, R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 J. Med. Chem. 2005, 48, 8045-8054 (Pubitemid 41798434)
54. Solomon, J. M.; Pasupuleti, R.; Xu, L.; McDonagh, T.; Curtis, R.; DiStefano, P. S.; Huber, L. J. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage Mol. and cell. biol. 2006, 26, 28-38
55. Outeiro, T. F.; Kontopoulos, E.; Altmann, S. M.; Kufareva, I.; Strathearn, K. E.; Amore, A. M.; Volk, C. B.; Maxwell, M. M.; Rochet, J. C.; McLean, P. J.; Young, A. B.; Abagyan, R.; Feany, M. B.; Hyman, B. T.; Kazantsev, A. G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease Science 2007, 317, 516-519 (Pubitemid 47196116)
56. Wang, T. T.; Schoene, N. W.; Kim, E. K.; Kim, Y. S. Pleiotropic effects of the sirtuin inhibitor sirtinol involves concentration-dependent modulation of multiple nuclear receptor-mediated pathways in androgen-responsive prostate cancer cell LNCaP. Mol. Carcinog. 2012, DOI 10.1002/mc.21906.
57. Ricci-Vitiani, L.; Lombardi, D. G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells Nature 2007, 445, 111-115 (Pubitemid 46067311)
58. Ricci-Vitiani, L.; Pallini, R.; Larocca, L. M.; Lombardi, D. G.; Signore, M.; Pierconti, F.; Petrucci, G.; Montano, N.; Maira, G.; De Maria, R. Mesenchymal differentiation of glioblastoma stem cells Cell Death Differ. 2008, 15, 1491-1498